Which is better, LLY or PCVX?

On the Buffett-Fit framework, Eli Lilly and Company (LLY) currently grades higher than PCVX — 72/100 (B grade) vs 15/100 (F). That said, "better" depends on which framework you trust — LLY wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; PCVX wins on none. The full pillar breakdown is on this page.

Should I buy LLY or PCVX?

This page is an educational comparison, not investment advice. Both LLY and PCVX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is LLY better than PCVX for value investing?

On the Buffett-style value-investing framework, LLY currently grades higher — 72/100 vs 15/100, a 57-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between LLY and PCVX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). LLY currently scores 72/100 (B grade); PCVX scores 15/100 (F grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, LLY or PCVX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. LLY and PCVX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, LLY or PCVX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are LLY and PCVX both Healthcare stocks?

Yes — both Eli Lilly and Company (LLY) and Vaxcyte, Inc. (PCVX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this LLY vs PCVX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Eli Lilly

LLY

Market cap

$974.4B

Sector

Healthcare

Overall winner

Eli Lilly

LLY 7–0 PCVX

Vaxcyte

PCVX

Market cap

$6.81B

Sector

Healthcare

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

LLYvsPCVX

Warren Buffett

72B

15F

Benjamin Graham

86A

46D

Philip Fisher

86A

36D

Peter Lynch

74B

11F

Joel Greenblatt

78C

Charlie Munger

85A

25F

Terry Smith

77C

30F

Side-by-side metrics

Metric	LLY	PCVX
Market cap	$974.4B	$6.81B
P/E (TTM)	36.6x	-
EV/EBIT	34.1x	-
ROIC (TTM)	32.06%	-34.98%
Gross margin	83.51%	0.0%
Net margin	34.98%	0.0%
Revenue CAGR 5y	23.17%	-
EPS CAGR 5y	40.81%	-
Debt / Equity	1.4x	0.0x
Dividend yield	0.62%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

LLY leads on

ROIC (TTM)32.06%vs -34.98%+192%
Gross margin83.51%vs 0.0%+100%
Net margin34.98%vs 0.0%+100%
Dividend yield0.62%vs 0.0%+100%

PCVX leads on

EV/EBIT-vs 34.1x+124%
P/E (TTM)-vs 36.6x+121%
Debt / Equity0.0xvs 1.4x+97%

More like LLY

LLY vs JSLL.NS LLY vs JSLL.BO LLY vs 4728.TWO LLY vs CAMX.ST LLY vs PME.AX LLY vs HALO

More like PCVX

PCVX vs JSLL.NS PCVX vs JSLL.BO PCVX vs 4728.TWO PCVX vs CAMX.ST PCVX vs PME.AX PCVX vs HALO

Read the full Buffett-Brain analysis for LLY Read the full Buffett-Brain analysis for PCVX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Eli Lilly

LLY

Market cap

$974.4B

Sector

Healthcare

Overall winner

Eli Lilly

LLY 7–0 PCVX

Vaxcyte

PCVX

Market cap

$6.81B

Sector

Healthcare

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

LLYvsPCVX

Warren Buffett

72B

15F

Benjamin Graham

86A

46D

Philip Fisher

86A

36D

Peter Lynch

74B

11F

Joel Greenblatt

78C

Charlie Munger

85A

25F

Terry Smith

77C

30F

Side-by-side metrics

Metric	LLY	PCVX
Market cap	$974.4B	$6.81B
P/E (TTM)	36.6x	-
EV/EBIT	34.1x	-
ROIC (TTM)	32.06%	-34.98%
Gross margin	83.51%	0.0%
Net margin	34.98%	0.0%
Revenue CAGR 5y	23.17%	-
EPS CAGR 5y	40.81%	-
Debt / Equity	1.4x	0.0x
Dividend yield	0.62%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

LLY leads on

ROIC (TTM)32.06%vs -34.98%+192%
Gross margin83.51%vs 0.0%+100%
Net margin34.98%vs 0.0%+100%
Dividend yield0.62%vs 0.0%+100%

PCVX leads on

EV/EBIT-vs 34.1x+124%
P/E (TTM)-vs 36.6x+121%
Debt / Equity0.0xvs 1.4x+97%

More like LLY

LLY vs JSLL.NS LLY vs JSLL.BO LLY vs 4728.TWO LLY vs CAMX.ST LLY vs PME.AX LLY vs HALO

More like PCVX

PCVX vs JSLL.NS PCVX vs JSLL.BO PCVX vs 4728.TWO PCVX vs CAMX.ST PCVX vs PME.AX PCVX vs HALO

Read the full Buffett-Brain analysis for LLY Read the full Buffett-Brain analysis for PCVX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.